OncoHost

OncoHost is a commercial-stage precision oncology company that uses bioinformatic proteomic pattern recognition and AI to personalize cancer therapy decisions. Its flagship product, PROphet®, is a plasma-based test that predicts patient benefit from PD-1/PD-L1 inhibitors by analyzing the biological interplay between the patient, tumor, and therapy — enabling oncologists to make more informed treatment planning decisions. Founded in 2017 and headquartered in Binyamina, Israel with US operations in Cary, NC, OncoHost has raised over $35M including a Series C round in 2022.